Business
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will host an expert physician panel discussion during an ancillary event at the 67th American Society of Hemat
About this update from Caribou Biosciences, Inc.
[{"type":"image","alt":"Caribou Biosciences, Inc.","displaySize":"","headline":null,"caption":"Caribou Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/daefc0c372fe0c4b67822f8b9179087c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Rnd4qeRJ_xjp9Qy6VyL25w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/daefc0c372fe0c4b67822f8b9179087c","width":300,"height":74}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting","length":197,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":197,"olType":false},{"type":"text","content":"BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will host an expert physician panel discussion during an ancillary event at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. The session will focus on how vispa-cel, Caribou’s allogeneic anti-CD19 CAR-T cell therapy, has the potential to expand patient access by enabling readily available CAR-T cell therapy care within sophisticated community hospitals and academic centers.","length":596,"tagName":"p"},{"type":"text","content":"The event will be held in-person at the Hyatt Regency Orlando starting at 7:30AM ET on Saturday, December 6, 2025 and will be available virtually via webcast. The event will be moderated by Tina Albertson, MD, PhD, Caribou’s chief medical officer, and feature insights from leading physicians from community hospitals and academic centers:","length":339,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Wayne Ormsby, MD – Utah Cancer Specialists","length":42,"tagName":"p"}]},{"val":[{"type":"text","content":"Justin Thomas, MD – Bozeman Health","length":34,"tagName":"p"}]},{"val":[{"type":"text","content":"Mehdi Hamadani, MD – Medical College of Wisconsin","length":49,"tagName":"p"}]},{"val":[{"type":"text","content":"Joseph McGuirk, DO – University of Kansas Cancer Center","length":55,"tagName":...